Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Noraramtide by Biohaven for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Noraramtide is under clinical development by Biohaven and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData,...